Antiretroviral therapy coverage for PMTCT in Panama

Panama: Antiretroviral therapy coverage for PMTCT was 86.0% in 2024. ▲ Rising

Latest (2024)
86.0%
Change on year
down 12.2%
World rank
34th
of 84 countries
All-time high
98.0%
in 2023
All-time low
16.0%
in 2000
Years of data
25
2000–2024

Antiretroviral therapy coverage for PMTCT in Panama, 2000–2024

204060801002000201220242000: 16 % of pregnant women living with HIV2001: 22 % of pregnant women living with HIV2002: 27 % of pregnant women living with HIV2003: 26 % of pregnant women living with HIV2004: 24 % of pregnant women living with HIV2005: 60 % of pregnant women living with HIV2006: 59 % of pregnant women living with HIV2007: 44 % of pregnant women living with HIV2008: 66 % of pregnant women living with HIV2009: 70 % of pregnant women living with HIV2010: 71 % of pregnant women living with HIV2011: 80 % of pregnant women living with HIV2012: 79 % of pregnant women living with HIV2013: 91 % of pregnant women living with HIV2014: 77 % of pregnant women living with HIV2015: 83 % of pregnant women living with HIV2016: 76 % of pregnant women living with HIV2017: 80 % of pregnant women living with HIV2018: 74 % of pregnant women living with HIV2019: 66 % of pregnant women living with HIV2020: 66 % of pregnant women living with HIV2021: 88 % of pregnant women living with HIV2022: 87 % of pregnant women living with HIV2023: 98 % of pregnant women living with HIV2024: 86 % of pregnant women living with HIV

Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of pregnant women living with HIV.

Analysis

In 2024, antiretroviral therapy coverage for pmtct in Panama stood at 86.0%.

Compared with earlier readings it is down 12.2% on the previous year and up 11.7% over ten years.

Over the whole period, antiretroviral therapy coverage for pmtct in Panama peaked at 98.0% in 2023 and was at its lowest, 16.0%, in 2000.

Panama ranks 34th of 84 countries on this measure, in the middle of the range.

The long-run direction has been consistently rising across the 25 years of available data.

Antiretroviral therapy coverage for PMTCT in Panama, year by year

Annual values for Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV) in Panama, 2000 to 2024.
Year % of pregnant women living with HIV Change
2000 16.0%
2001 22.0% +37.5%
2002 27.0% +22.7%
2003 26.0% -3.7%
2004 24.0% -7.7%
2005 60.0% +150.0%
2006 59.0% -1.7%
2007 44.0% -25.4%
2008 66.0% +50.0%
2009 70.0% +6.1%
2010 71.0% +1.4%
2011 80.0% +12.7%
2012 79.0% -1.2%
2013 91.0% +15.2%
2014 77.0% -15.4%
2015 83.0% +7.8%
2016 76.0% -8.4%
2017 80.0% +5.3%
2018 74.0% -7.5%
2019 66.0% -10.8%
2020 66.0% +0.0%
2021 88.0% +33.3%
2022 87.0% -1.1%
2023 98.0% +12.6%
2024 86.0% -12.2%

Panama compared with similar countries

  • Panama's 86.0% is below the median for high income countries, which is 89.0%, 97% of the median. (8 countries reporting)
  • Panama's 86.0% is above the median for Latin America & Caribbean, which is 68.0%, 1.3× the median. (15 countries reporting)

Biggest year-on-year movements

Years where Antiretroviral therapy coverage for PMTCT in Panama changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.

YearChange FromTo
2005 +150.0% 24.0% 60.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 41.4% 16.0% 70.0% 10
2010s 77.7% 66.0% 91.0% 10
2020s 85.0% 66.0% 98.0% 5

Countries ranked near Panama

  1. 31 Cote d'Ivoire 88.0% compare
  2. 31 Liberia 88.0% compare
  3. 33 Togo 87.0% compare
  4. 35 Ecuador 85.0% compare
  5. 35 Vietnam 85.0% compare
  6. 37 Guyana 84.0% compare

See the full ranking of 99 places →

More health data for Panama

All data for Panama →

Frequently asked questions

What is antiretroviral therapy coverage for pmtct in Panama?
Antiretroviral therapy coverage for pmtct in Panama was 86.0% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
What is the highest antiretroviral therapy coverage for pmtct recorded in Panama?
The highest recorded value was 98.0% in 2023.
What is the lowest antiretroviral therapy coverage for pmtct recorded in Panama?
The lowest recorded value was 16.0% in 2000.
How does Panama rank for antiretroviral therapy coverage for pmtct?
Panama ranks 34th out of 84 countries with data for 2024.
Is antiretroviral therapy coverage for pmtct rising or falling in Panama?
Over the last ten years it is up 11.7%. The long-run trend across the full record is rising.
Where does this Panama data come from?
The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Antiretroviral therapy coverage for PMTCT in Panama. Statizoid, drawing on UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Retrieved 17 September 2026, from https://health.statizoid.com/stat/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/panama/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://health.statizoid.com/stat/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/panama/">Antiretroviral therapy coverage for PMTCT in Panama</a> — Statizoid

About this data

Indicator
Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV)
Unit
% of pregnant women living with HIV
Source
UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS)
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
99 places, 2,393 data points, 2000–2024
Last refreshed

Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).